Dual-listed cancer diagnostics company Pacific Edge has gone into a trading halt this morning, with Jarden and Forsyth Barr both publishing research notes saying that Novitas had decided the company’s Cxbladder tests will not be covered by US national health insurance provider Medicare.
Jarden’s
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
